Completed PHASE3 INTERVENTIONAL NCT00016380

Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen

A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis

Sponsor: NCIC Clinical Trials Group

Conditions Cancer

Interventions dexamethasone ondansetron quality-of-life assessment

Updated 7 times since 2017 Last updated: Apr 1, 2020 Started: Feb 28, 2001 Primary completion: Apr 30, 2004 Completion: Feb 10, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cancer and is currently completed. NCIC Clinical Trials Group leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

NCIC Clinical Trials Group

Data source: Canadian Cancer Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Edmonton, Canada , Fleurimont, Canada , Halifax, Canada , Kelowna, Canada , London, Canada , Montreal, Canada , Québec, Canada , Surrey, Canada , Thunder Bay, Canada , Toronto, Canada and 1 more location